SCD-HeFT results published: more ICD (implantable cardioverter defibrillator) eligibility now in US?
This article was originally published in Clinica
The number of Medicare beneficiaries eligible to receive an implantable cardioverter defibrillator (ICD) as a primary prevention against sudden cardiac death (SCD) could more than double, now that the results of Medtronic's SCD-HeFT trial have finally appeared in a peer-reviewed medical journal.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.